Overview

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor College of Medicine
Treatments:
Dexmedetomidine